Press release
Investors who lost money with shares of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) should contact the Shareholders Foundation in connection with Lawsuit
A lawsuit was filed on behalf of investors in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) shares.
Investors who purchased shares of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) have certain options and for certain investors are short and strict deadlines running. Deadline: August 11, 2025. NASDAQ: RCKT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Cranbury, NJ based Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) reported that its Net Loss increased from $245.59 million in 2023 to $258.74 million in 2024.
On May 27, 2025, Rocket Pharmaceuticals, Inc. announced that the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after at least one patient suffered a Serious Adverse Event (SAE), ultimately, death, while enrolled in the study following a substantive amendment to the protocol that the Company failed to disclose to investors at the time management made the revision. In fact, Rocket Pharmaceuticals, Inc. stated that, while the patient was dosed in May, the decision to amend the protocol was made "several months" earlier. Despite this, Rocket Pharmaceuticals, Inc. made no attempt to alert investors or the public to the change until after the SAE occurred.
Shares of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) declined from $9.80 per share on February 27, 2025, to as low as $2.19 per share on May 27, 2025.
The plaintiff claims that between February 27, 2025, to May 26, 2025, the Defendants provided investors with material information concerning Rocket's Phase 2 pivotal trial of RP-A501 for the treatment of Danon disease, that the Defendants' statements included, among other things, confidence in the drug's safety and efficacy, as well as the clinical trial's detailed protocol and Rocket's purported ability to meet the trial's endpoints as per the Company's ascribed timeline, and that the defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RPA501's safety and clinical trial protocol; notably, that Rocket knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk. In particular, Rocket amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders.
Those who purchased shares of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investors who lost money with shares of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) should contact the Shareholders Foundation in connection with Lawsuit here
News-ID: 4073051 • Views: …
More Releases from Shareholders Foundation, Inc.
Novo Nordisk A/S (NYSE: NVO) Long Term Investor Alert: Investigation of potentia …
An investigation on behalf of current long-term investors in shares of Novo Nordisk A/S (NYSE: NVO) concerning potential breaches of fiduciary duties by certain directors and officers was announced.
Investors who are current long term investors in Novo Nordisk A/S (NYSE: NVO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for long term investors in…
Lawsuit filed for Investors who lost money with shares of Fortinet, Inc. (NASDAQ …
An investor, who purchased shares of Fortinet, Inc. (NASDAQ: FTNT), filed a lawsuit over alleged violations of Federal Securities Laws by Fortinet, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fortinet, Inc. (NASDAQ: FTNT) have certain options and for certain investors are short and strict deadlines running. Deadline: November 21, 2025. NASDAQ: FTNT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
CTO Realty Growth, Inc. (NYSE: CTO) Investor Alert: Deadline in Lawsuit on Octob …
A deadline is coming up on October 07, 2025in the lawsuit filed for certain investors of CTO Realty Growth, Inc. (NYSE: CTO) over alleged securities laws violations by CTO Realty Growth, Inc.
Investors who purchased shares of CTO Realty Growth, Inc. (NYSE: CTO) have certain options and there are strict and short deadlines running. Deadline: October 07, 2025. CTO Realty Growth, Inc. (NYSE: CTO) stockholders should contact the Shareholders Foundation at…
Alert: Lawsuit filed for Investors who lost money with shares of Jasper Therapeu …
An investor, who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR), filed a lawsuit over alleged violations of Federal Securities Laws by Jasper Therapeutics, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 18, 2025. NASDAQ: JSPR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Rocket
Rocket Hybrid Propulsion Market to Reach $2 Billion by 2031, Rocket Motor Segmen …
According to a new report published by Allied Market Research, titled, "Rocket Hybrid Propulsion Market Size, Share, Competitive Landscape and Trend Analysis Report, by Type, by Orbit, by Component, by Vehicle Type, by End User : Global Opportunity Analysis and Industry Forecast, 2021-2031". The research provides a current evaluation of the global market landscape, highlighting recent trends, key drivers, and the overall market environment. The study examines the main factors…
Key Influencer in the Rocket Engines Market 2025: Surge In Rocket Launches Boost …
What combination of drivers is leading to accelerated growth in the rocket engines market?
The rocket engines market is projected to expand due to the rise in rocket launches in the forecasted period. In the coming ten years, a multitude of enterprises and governmental institutions globally have proposals to launch rockets and deploy numerous satellites in large constellations in low-Earth orbit. For example, as reported by the U.S. International Trade Commission,…
Prominent Rocket and Missile Market Trend for 2025: Strategic Innovations In The …
What market dynamics are playing a key role in accelerating the growth of the rocket and missile market?
The increase in terrorist activities and geopolitical uncertainties is anticipated to propel the expansion of the rockets and missiles market. Terrorism, characterized by employing threat or violent acts to instill fear, aims to manipulate or compel a government and its citizens to advocate specific political or societal objectives. Such conflict and extreme political…
Rocket Propulsion Market
The "Rocket Propulsion Market" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031. The market was valued at USD xx.x billion In 2023.
Growing Demand and Growth Potential in the Global Rocket Propulsion Market, 2024-2031
Verified Market Research's most recent report, "Rocket Propulsion Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2030," provides an in-depth examination…
Rocket Liquid Propulsion Market Growth Outlook to 2028 - ROCKET LAB USA, Safran, …
Rocket Liquid Propulsion Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Rocket Motor, Rocket Engine); Orbit (Low Earth Orbit (LEO), Medium Earth Orbit (MEO), Geostationary Earth Orbit (GEO), Beyond Geosynchronous Orbit (BGEO)); End-user (Military and Government, Commercial) and Geography
A rocket may be an aircraft, a spacecraft, a missile, or some other thrust-generating vehicle. The rockets propulsion system generates thrust. Strong, liquid, and hybrid propellants are used…
Model Rocket Market Evaluation with Key Companies Estes Rockets, Madcow Rocketry …
“Model Rocket Market 2019-2026” report gives distinctive insights worldwide market competition for Model Rocket. Focusing on objectives of this report is to categorize dynamics of the market and to supply latest updates like mergers and acquisitions, numerous technological developments, new entrants within the market, that create an impression on totally different segments of the Model Rocket market.
Get Detail Sample: https://inforgrowth.com/sample-request/6337318/model-rocket-market
Top-Manufacturers of Model Rocket market
Estes Rockets, Madcow Rocketry, Custom Rocket Company,…
